{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:12:19Z","timestamp":1793506339562,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI ponatinib is effective against BCR-ABL1 point mutants individually, but remains vulnerable to certain BCR-ABL1 compound mutants. To determine the frequency of compound mutations among chronic myeloid leukemia patients on ABL1 TKI therapy, in the present study, we examined a collection of patient samples (N = 47) with clear evidence of 2 BCR-ABL1 kinase domain mutations by direct sequencing. Using a cloning and sequencing method, we found that 70% (33\/47) of double mutations detected by direct sequencing were compound mutations. Sequential, branching, and parallel routes to compound mutations were common. In addition, our approach revealed individual and compound mutations not detectable by direct sequencing. The frequency of clones harboring compound mutations with more than 2 missense mutations was low (10%), whereas the likelihood of silent mutations increased disproportionately with the total number of mutations per clone, suggesting a limited tolerance for BCR-ABL1 kinase domain missense mutations. We conclude that compound mutations are common in patients with sequencing evidence for 2 BCR-ABL1 mutations and frequently reflect a highly complex clonal network, the evolution of which may be limited by the negative impact of missense mutations on kinase function.<\/jats:p>","DOI":"10.1182\/blood-2012-05-431379","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T02:49:16Z","timestamp":1354762156000},"page":"489-498","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":195,"title":["BCR-ABL1 compound mutations in tyrosine kinase inhibitor\u2013resistant CML: frequency and clonal relationships"],"prefix":"10.1182","volume":"121","author":[{"given":"Jamshid S.","family":"Khorashad","sequence":"first","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Kelley","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Szankasi","sequence":"additional","affiliation":[{"name":"Research and Development, ARUP Laboratories, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton C.","family":"Mason","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, L. e A. Seragnoli, University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren T.","family":"Adrian","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR;"},{"name":"Howard Hughes Medical Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Zabriskie","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Leipzig, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C.","family":"Estrada","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Pomicter","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Eiring","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira L.","family":"Kraft","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Gu","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Alikian","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imperial College London, Hammersmith Hospital, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair G.","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imperial College London, Hammersmith Hospital, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Foroni","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imperial College London, Hammersmith Hospital, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imperial College London, Hammersmith Hospital, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR;"},{"name":"Howard Hughes Medical Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O'Hare","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"},{"name":"Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"},{"name":"Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"24","key":"2019111809265231100_B1","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111809265231100_B2","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111809265231100_B3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"20","key":"2019111809265231100_B4","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111809265231100_B5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111809265231100_B6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"9305","key":"2019111809265231100_B7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"issue":"5531","key":"2019111809265231100_B8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"1","key":"2019111809265231100_B9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111809265231100_B10","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Research"},{"issue":"3","key":"2019111809265231100_B11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111809265231100_B12","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111809265231100_B13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"21","key":"2019111809265231100_B14","first-page":"1416","article-title":"Resistance profiling of BCR-ABL compound mutations linked to tyrosine kinase inhibitor therapy failure in chronic myeloid leukemia [abstract].","volume":"118","author":"Eide","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"2019111809265231100_B15","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111809265231100_B16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2019111809265231100_B17","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111809265231100_B18","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"27","key":"2019111809265231100_B19","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"issue":"s1","key":"2019111809265231100_B20","first-page":"371","article-title":"Dasatinib efficacy after imatinib failure by dosing schedule and baseline BCR-ABL mutation status in patients with chronic myeloid leukemia in chronic phase (CML-CP).","volume":"93","author":"Hochhaus","year":"2008","journal-title":"Haematologia"},{"issue":"24","key":"2019111809265231100_B21","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"issue":"32","key":"2019111809265231100_B22","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","article-title":"Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.","volume":"29","author":"Parker","year":"2011","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111809265231100_B23","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"The finding of kinase domain mutations in chronic phase CML patients responding to imatinib may identify those at high risk of disease progression.","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111809265231100_B24","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood-2011-08-375535","article-title":"Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.","volume":"119","author":"Parker","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111809265231100_B25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.22272","article-title":"BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation.","volume":"87","author":"Alikian","year":"2012","journal-title":"Am J Hematol"},{"issue":"9","key":"2019111809265231100_B26","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111809265231100_B27","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","article-title":"Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).","volume":"108","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111809265231100_B28","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","article-title":"Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.","volume":"109","author":"Ray","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111809265231100_B29","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"issue":"24","key":"2019111809265231100_B30","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111809265231100_B31","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2019111809265231100_B32","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111809265231100_B33","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"issue":"10","key":"2019111809265231100_B34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"2019111809265231100_B35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bioinformatics\/btq630","article-title":"Identifying cancer driver genes in tumor genome sequencing studies.","volume":"27","author":"Youn","year":"2011","journal-title":"Bioinformatics"},{"issue":"16","key":"2019111809265231100_B36","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of bcr-abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"51","key":"2019111809265231100_B37","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2019111809265231100_B38","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.","volume":"71","author":"Eide","year":"2011","journal-title":"Cancer Res"},{"issue":"10","key":"2019111809265231100_B39","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"},{"issue":"7239","key":"2019111809265231100_B40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome.","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/3\/489\/1366430\/zh800313000489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/3\/489\/1366430\/zh800313000489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:27:27Z","timestamp":1574072847000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/3\/489\/30994\/BCRABL1-compound-mutations-in-tyrosine-kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,17]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,1,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-431379","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,17]]}}}